

Giuseppina Brancaccio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/307563/publications.pdf>

Version: 2024-02-01

54
papers

1,526
citations

331538

21
h-index

315616

38
g-index

55
all docs

55
docs citations

55
times ranked

2411
citing authors

#	ARTICLE	IF	CITATIONS
1	Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues. <i>Gastroenterology</i> , 2012, 143, 963-973.e9.	0.6	308
2	Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. <i>Hepatology</i> , 2006, 44, 713-720.	3.6	222
3	Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. <i>Liver International</i> , 2017, 37, 514-528.	1.9	84
4	Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas. <i>European Journal of Internal Medicine</i> , 2018, 53, 79-84.	1.0	69
5	Fever of unknown origin (FUO): which are the factors influencing the final diagnosis? A 2005-2015 systematic review. <i>BMC Infectious Diseases</i> , 2019, 19, 653.	1.3	64
6	Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. <i>PLoS ONE</i> , 2017, 12, e0172159.	1.1	42
7	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. <i>Digestive and Liver Disease</i> , 2018, 50, 1105-1114.	0.4	41
8	Influenza vaccination in patients with cirrhosis and in liver transplant recipients. <i>Vaccine</i> , 2009, 27, 3373-3375.	1.7	39
9	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , 2017, 12, e0185728.	1.1	37
10	Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1071-1076.	1.9	35
11	Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide survey. <i>Digestive and Liver Disease</i> , 2016, 48, 1066-1071.	0.4	34
12	Hepatitis delta infection in Italian patients: towards the end of the story?. <i>Infection</i> , 2017, 45, 277-281.	2.3	34
13	Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?. <i>Liver International</i> , 2018, 38, 2190-2198.	1.9	33
14	Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study. <i>Liver International</i> , 2019, 39, 1852-1859.	1.9	31
15	HBV DNA suppression and HBsAg clearance in HBsAg negative chronic hepatitis B patients on lamivudine therapy for over 5years. <i>Journal of Hepatology</i> , 2012, 56, 1254-1258.	1.8	29
16	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. <i>Journal of Hepatology</i> , 2018, 68, 597-600.	1.8	28
17	Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. <i>Journal of Hepatology</i> , 2014, 60, 16-21.	1.8	25
18	Different changes in mitochondrial apoptotic pathway in lymphocytes and granulocytes in cirrhotic patients with sepsis. <i>Liver International</i> , 2013, 33, 834-842.	1.9	24

#	ARTICLE	IF	CITATIONS
19	Ultra-deep sequencing reveals high prevalence and broad structural diversity of hepatitis B surface antigen mutations in a global population. <i>PLoS ONE</i> , 2017, 12, e0172101.	1.1	24
20	Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. <i>Digestive and Liver Disease</i> , 2011, 43, 875-80.	0.4	23
21	Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology. <i>European Journal of Internal Medicine</i> , 2017, 38, 68-72.	1.0	23
22	HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study. <i>Digestive and Liver Disease</i> , 2017, 49, 1022-1028.	0.4	19
23	The present profile of chronic hepatitis B virus infection highlights future challenges. <i>Digestive and Liver Disease</i> , 2019, 51, 438-442.	0.4	17
24	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	3.7	15
25	Active recruitment strategy in disadvantaged immigrant populations improves the identification of human immunodeficiency but not of hepatitis B or C virus infections. <i>Digestive and Liver Disease</i> , 2014, 46, 62-66.	0.4	14
26	Virological patterns of HCV patients with failure to interferon-free regimens. <i>Journal of Medical Virology</i> , 2018, 90, 942-950.	2.5	14
27	Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross-sectional multicenter study. <i>Journal of Medical Virology</i> , 2017, 89, 2138-2143.	2.5	13
28	NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients. <i>Cells</i> , 2019, 8, 666.	1.8	13
29	Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1603.	0.9	12
30	Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 977-978.	2.4	12
31	Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort. <i>BMC Infectious Diseases</i> , 2021, 21, 413.	1.3	12
32	A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. <i>Hepatology</i> , 2022, 76, 220-232.	3.6	12
33	Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 697-701.	1.1	11
34	An Increase in the Levels of Middle Surface Antigen Characterizes Patients Developing HBV-Driven Liver Cancer Despite Prolonged Virological Suppression. <i>Microorganisms</i> , 2021, 9, 752.	1.6	10
35	Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir. <i>Liver International</i> , 2019, 39, 484-493.	1.9	9
36	Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy. <i>Pathogens and Global Health</i> , 2023, 117, 181-189.	1.0	9

#	ARTICLE	IF	CITATIONS
37	An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 818-825.	0.4	8
38	Changing indications for liver transplant: slow decline of hepatitis viruses in Italy. <i>Infectious Diseases</i> , 2020, 52, 557-562.	1.4	8
39	CD8 ⁺ T cells specific to apoptosis-associated epitopes are expanded in patients with chronic HBV infection and fibrosis. <i>Liver International</i> , 2021, 41, 470-481.	1.9	7
40	Hepatitis C Virus Clearance in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 85-91.	1.3	6
41	Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required?. <i>Digestive and Liver Disease</i> , 2017, 49, 197-201.	0.4	5
42	Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment. <i>Antiviral Therapy</i> , 2019, 24, 485-493.	0.6	5
43	AISF position paper on HCV in immunocompromised patients. <i>Digestive and Liver Disease</i> , 2019, 51, 10-23.	0.4	5
44	Prophylaxis of Hepatitis B Virus (HBV) Re-Infection in Liver Transplantation: Is the Reappearance of Hepatitis B Surface Antigen (HBsAg) Significant?. <i>Annals of Transplantation</i> , 2020, 25, e920969.	0.5	5
45	Individualized Treatment of Genotype 1 Naïve Patients: An Italian Multicenter Field Practice Experience. <i>PLoS ONE</i> , 2014, 9, e110284.	1.1	5
46	Is spleen circulation impaired in systemic sclerosis and what is the role of liver fibrosis?. <i>World Journal of Gastroenterology</i> , 2011, 17, 1606.	1.4	5
47	Interleukin-28B genetic variants in untreated Italian HCV-infected patients: a multicentre study. <i>Liver International</i> , 2015, 35, 482-488.	1.9	4
48	Bacterial pneumonia in patients with liver cirrhosis, with or without HIV co-infection: a possible definition of antibiotic prophylaxis associated pneumonia (APAP). <i>Infectious Diseases</i> , 2018, 50, 125-132.	1.4	4
49	Hepatitis C late relapse in patients with directly acting antiviral-related sustained virological response at week 12. <i>Liver International</i> , 2019, 39, 844-853.	1.9	4
50	Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy. <i>Medicine (United States)</i> , 2018, 97, e11307.	0.4	3
51	Sunscreen ingredients in plasma: a threat for drug-drug interactions and toxicity among patients living with HIV?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 775-778.	1.5	3
52	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. <i>Digestive and Liver Disease</i> , 2021, 53, 1603-1609.	0.4	2
53	Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedication used in the PITER cohort. <i>Antiviral Therapy</i> , 2020, 25, 73-81.	0.6	2
54	Letter: clinical outcomes of patients with hepatitis D infection in the liver transplant setting—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 484-484.	1.9	1